Antihypertensive prescribing patterns in non-dialysis dependent chronic kidney disease: Findings from the Salford Kidney Study

Table 4 Number of patients prescribed with each antihypertensive class at baseline, organized by urine albumin-creatinine ratio categories at baseline

Antihypertensive class	uACR < 30, n = 13551,2	uACR 30-300, n = 12361,2	uACR > 300, n = 2481,2	Total, n = 28391,3	P value1
None	148 (10.9)	112 (9.1)	12 (4.8)	272 (9.6)	< 0.001
Three or more agents	547 (40.4)	530 (42.9)	155 (62.5)	1232 (43.4)	< 0.001
Diuretic (thiazide and loop)	656 (48.4)	542 (43.9)	148 (59.7)	1346 (47.4)	< 0.001
CCB (dihydropyridine)	477 (35.2)	516 (41.7)	122 (49.2)	1115 (39.3)	< 0.001
CCB (non- dihydropyridine)	61 (4.5)	54 (4.4)	11 (4.4)	126 (4.4)	0.987
Beta-blocker	458 (33.8)	418 (33.8)	93 (37.5)	969 (34.1)	0.504
Alpha blocker	265 (19.6)	335 (27.1)	87 (35.1)	687 (24.2)	< 0.001
Central agent	45 (3.3)	69 (5.6)	23 (9.3)	137 (4.8)	< 0.001
Vasodilator	11 (0.8)	16 (1.3)	1 (0.4)	28 (1.0)	0.288
RAS blocker	840 (62.0)	753 (61.0)	174 (70.2)	1767 (62.2)	0.023
Dual RAS blockers	49 (3.6)	80 (6.5)	41 (16.5)	170 (6.0)	< 0.001
Spironolactone/eplerenone	52 (3.8)	29 (2.3)	11 (4.4)	92 (3.2)	0.054

¹Absolute number for frequencies (percentages). The P values were calculated by the χ² test.

²uACR in mg/mg = -0.171 + 0.780 urine protein-creatinine ratio in mg/mg.

³Total was 2839 rather than 3230 as in previous tables as some patients were missing uACR data.

CCB: Calcium channel blocker; RAS: Renin angiotensin system; uACR: Urine albumin-creatinine ratio in mg/g.